Key facts
- Octarine Bio’s last known valuation is $30.8M (Jan 2026).
- It has raised $16.8M; the latest was Later Stage VC ($11.0M) in Jan 2026.
- Notable investors include InnoFounder, Denmark's Export and Investment Fund, BioInnovation Institute, Unconventional Ventures, Bruce Linton — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Octarine Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Octarine Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Octarine Bio
Developer of cannabinoids and psilocybin derivatives intended to improve the health and well-being of people. The company harnesses synthetic biology using its biosynthetic platform to develop a range of natural and novel cannabinoid and psilocybin-derived molecules with improved pharmacokinetic and therapeutic properties, enabling healthcare professionals to treat neurological and psychological disorders.
- Sector
- Healthcare
- HQ
- Copenhagen, Denmark
- Founded
- 2018
- Employees
- 27
- Website
- octarinebio.com/
- Ownership
- Privately Held (backing)
Octarine Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Octarine Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Octarine Bio in its N-PORT filings yet. We sweep new filings monthly.